Inside a $175M Deal: Tim McLoughlin & Joshua Hayes Live From RDU Startup Week
What's Shaping the Capital Raising Environment?
Raising a Down Round and How to Be Prepared
Developing an AI Policy for Your Startup
Due Diligence in AI: Thinking like your biggest critic
JONES DAY TALKS®: A Trip to the Dark Side – Venture Capital Down Rounds and Recaps
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
Embracing Change & Community: The Keys To Startup Success With Chris Heivly
The Best of Founder Shares: Highlights Wisdom of Season's Guests
A Conversation with Janade du Plessis of Launch Africa Ventures: Balancing Sustainable Development with ROI
The Force is Strong with this One – Success and Paying it Forward with Co-Founder of ChannelAdvisor and Spiffy Scot Wingo
Hunting Outsized Returns with Jason Caplain of Bull City Venture Partners
Through the Lens: From serial entrepreneur to neutral who gets deals done - Focus on Daniel Garrie
A View From the Starting Line – A Conversation with Teenpreneur Tierney Schmidt
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 159: Bob Quinn, Executive Director, and Adrianne Grimes, Director of Marketing and Comms, SCRA
From Accidental Entrepreneur to a $2.5M raise, with Cycle Labs' Josh Owen
The One Reason Startups Fail, with VentureSouth's Charlie Banks
When Two is Better Than One: Murphy’s Naturals and The Loading Dock Story with Philip Freeman
Huddling with Hutch adVENTURES: Behind the scenes with an early-stage venture capital firm
From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more
Investor interest in the medtech sector is strong. According to DealForma and JPMorgan, medtech companies raised $16.1 billion from 544 funding rounds, including $3.3 billion from 244 seed and Series A rounds, through the...more
01 A conversation with Evercore on the market outlook 02 Will there be an alternative path to public? 03 What’s ahead for tech and life sciences IPOs? 04 The Download Quiz: Venture Capital Trends / 01A CONVERSATION WITH...more
Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more
Wilson Sonsini’s 31st Annual Medical Device & Digital Health Conference will address topics of critical importance to medical device and digital health companies, including early and late-stage venture financing, partnering...more
Our last two alerts in this series covered key considerations for early-stage companies in the alternative protein industry and provided an overview of financing in the alternative protein industry. This alert follows those...more
The life sciences industry depended historically on public offerings for fundraising to support costs of developing therapeutic pharmaceutical and biologic products. The average cost of discovering and developing these...more
This week, our hosts Matthew and Heather are joined by Adrianne Grimes and Bob Quinn, leaders of the South Carolina Research Authority (SCRA). Our guests share how they have been able to fuel South Carolina’s innovation...more
Turning innovation into a successful business can be daunting. In a panel discussion at the 2023 BIO International Convention, Mintz’s Josh Fox, who is a Member in our Chambers-ranked Life Sciences practice, alongside...more
Wilson Sonsini’s 30th Annual Medical Device Digital Health Conference will address topics of critical importance to medical device and digital health companies today, including key healthcare regulatory considerations, the...more
Increased use of earnouts is likely to facilitate M&A deals across sectors in Europe. Earnouts are increasingly common in European M&A. The growing prevalence of this contractual provision — in which additional...more
In the early days of a life science company, there can be confusion and a number of landmines where legal missteps may happen. As part of our 2022 Startup & Accelerate Webinar Series, we look at five key commercial agreements...more
At the Life Sciences Dealmaking Symposium and Investment Forum, seasoned dealmakers, investors industry executives and technical experts will join McDermott's leading transactional, venture financing and private equity...more
In the last few years, and very much following in the footsteps of the US, the UK's life sciences sector has grown exponentially. This growth has been accelerated by Governmental support for the scientific community in the...more
The New Jersey Economic Recovery Act of 2020 (ERA), a seven-year, $14 billion package of incentive programs intended to encourage New Jersey job growth, property development and redevelopment, community partnerships, and...more
In a year marked by unexpected challenges and rapid change, staying connected with industry peers and keeping a watchful eye on market trends, policy developments and collaborations in the life sciences space is crucial to...more
The process of underwriting tenants can involve a range of important – and sometimes competing – considerations at the best of times. In the propsci space, this is further complicated by the particular requirements of early...more
The real estate needs of life sciences companies can be fluid and complex, with early stage companies typically needing smaller flexible space and later stage companies typically requiring larger build-to-suit space. With an...more
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the...more